Eintrag weiter verarbeiten
| author_facet |
Brown, Jennifer R. Brown, Jennifer R. |
|---|---|
| author |
Brown, Jennifer R. |
| spellingShingle |
Brown, Jennifer R. Blood How I treat CLL patients with ibrutinib Cell Biology Hematology Immunology Biochemistry |
| author_sort |
brown, jennifer r. |
| spelling |
Brown, Jennifer R. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-08-764712 <jats:title>Abstract</jats:title><jats:p>Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has been well tolerated. As its use has become more widespread in the community, however, its full adverse event profile has emerged and proven more challenging than was initially anticipated. Reports of community-based use have estimated discontinuation rates as high as 40% in the first year of therapy. This article therefore reviews my approach to the evaluation and management of a CLL patient starting on ibrutinib, with the goal of minimizing and managing toxicity to maintain patients on ibrutinib. Key topics discussed include bleeding risk; cardiac complications, particularly atrial fibrillation; drug interactions; and infections.</jats:p> How I treat CLL patients with ibrutinib Blood |
| doi_str_mv |
10.1182/blood-2017-08-764712 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA4LTc2NDcxMg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA4LTc2NDcxMg |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 |
| imprint |
American Society of Hematology, 2018 |
| imprint_str_mv |
American Society of Hematology, 2018 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
brown2018howitreatcllpatientswithibrutinib |
| publishDateSort |
2018 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
How I treat CLL patients with ibrutinib |
| title_unstemmed |
How I treat CLL patients with ibrutinib |
| title_full |
How I treat CLL patients with ibrutinib |
| title_fullStr |
How I treat CLL patients with ibrutinib |
| title_full_unstemmed |
How I treat CLL patients with ibrutinib |
| title_short |
How I treat CLL patients with ibrutinib |
| title_sort |
how i treat cll patients with ibrutinib |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2017-08-764712 |
| publishDate |
2018 |
| physical |
379-386 |
| description |
<jats:title>Abstract</jats:title><jats:p>Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has been well tolerated. As its use has become more widespread in the community, however, its full adverse event profile has emerged and proven more challenging than was initially anticipated. Reports of community-based use have estimated discontinuation rates as high as 40% in the first year of therapy. This article therefore reviews my approach to the evaluation and management of a CLL patient starting on ibrutinib, with the goal of minimizing and managing toxicity to maintain patients on ibrutinib. Key topics discussed include bleeding risk; cardiac complications, particularly atrial fibrillation; drug interactions; and infections.</jats:p> |
| container_issue |
4 |
| container_start_page |
379 |
| container_title |
Blood |
| container_volume |
131 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341791014387717 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:25:26.641Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=How+I+treat+CLL+patients+with+ibrutinib&rft.date=2018-01-25&genre=article&issn=1528-0020&volume=131&issue=4&spage=379&epage=386&pages=379-386&jtitle=Blood&atitle=How+I+treat+CLL+patients+with+ibrutinib&aulast=Brown&aufirst=Jennifer+R.&rft_id=info%3Adoi%2F10.1182%2Fblood-2017-08-764712&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341791014387717 |
| author | Brown, Jennifer R. |
| author_facet | Brown, Jennifer R., Brown, Jennifer R. |
| author_sort | brown, jennifer r. |
| container_issue | 4 |
| container_start_page | 379 |
| container_title | Blood |
| container_volume | 131 |
| description | <jats:title>Abstract</jats:title><jats:p>Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has been well tolerated. As its use has become more widespread in the community, however, its full adverse event profile has emerged and proven more challenging than was initially anticipated. Reports of community-based use have estimated discontinuation rates as high as 40% in the first year of therapy. This article therefore reviews my approach to the evaluation and management of a CLL patient starting on ibrutinib, with the goal of minimizing and managing toxicity to maintain patients on ibrutinib. Key topics discussed include bleeding risk; cardiac complications, particularly atrial fibrillation; drug interactions; and infections.</jats:p> |
| doi_str_mv | 10.1182/blood-2017-08-764712 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA4LTc2NDcxMg |
| imprint | American Society of Hematology, 2018 |
| imprint_str_mv | American Society of Hematology, 2018 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T16:25:26.641Z |
| match_str | brown2018howitreatcllpatientswithibrutinib |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 379-386 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Brown, Jennifer R. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-08-764712 <jats:title>Abstract</jats:title><jats:p>Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has been well tolerated. As its use has become more widespread in the community, however, its full adverse event profile has emerged and proven more challenging than was initially anticipated. Reports of community-based use have estimated discontinuation rates as high as 40% in the first year of therapy. This article therefore reviews my approach to the evaluation and management of a CLL patient starting on ibrutinib, with the goal of minimizing and managing toxicity to maintain patients on ibrutinib. Key topics discussed include bleeding risk; cardiac complications, particularly atrial fibrillation; drug interactions; and infections.</jats:p> How I treat CLL patients with ibrutinib Blood |
| spellingShingle | Brown, Jennifer R., Blood, How I treat CLL patients with ibrutinib, Cell Biology, Hematology, Immunology, Biochemistry |
| title | How I treat CLL patients with ibrutinib |
| title_full | How I treat CLL patients with ibrutinib |
| title_fullStr | How I treat CLL patients with ibrutinib |
| title_full_unstemmed | How I treat CLL patients with ibrutinib |
| title_short | How I treat CLL patients with ibrutinib |
| title_sort | how i treat cll patients with ibrutinib |
| title_unstemmed | How I treat CLL patients with ibrutinib |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2017-08-764712 |